Myovant's latest data paint a competitive picture
Myovant Sciences has reported more positive news about its once-daily combination pill to treat uterine fibroids, bolstering its case compared to AbbVie’s Oriahnn.
Two Phase 3 trials of relugolix already met their primary endpoints of improving symptoms in women with heavy menstrual bleeding and pelvic pain, compared to placebo. In an extension trial, the company reported virtually at a European scientific meeting, relugolix reduced distress over those symptoms and increased hemoglobin levels in the one-third of women who also had anemia. Women with anemia were more likely to be Black: 65.2% versus 51.2% of the study’s overall population.
Relugolix works by limiting the body’s production of ovarian estradiol, which spurs uterine fibroids and endometriosis, and testicular testosterone, which speeds prostate cancer. The combination pill adds back small amounts of estradiol and progestin to prevent hot flashes and preserve bone mineral density.
Baird analyst Brian Skorney wrote last month that Myovant’s better bone-density profile — a loss of 0.78% compared to AbbVie’s about 3% — plus its once-daily oral regimen could give it an edge.
Two Phase 3 trials of relugolix already met their primary endpoints of improving symptoms in women with heavy menstrual bleeding and pelvic pain, compared to placebo. In an extension trial, the company reported virtually at a European scientific meeting, relugolix reduced distress over those symptoms and increased hemoglobin levels in the one-third of women who also had anemia. Women with anemia were more likely to be Black: 65.2% versus 51.2% of the study’s overall population.
Relugolix works by limiting the body’s production of ovarian estradiol, which spurs uterine fibroids and endometriosis, and testicular testosterone, which speeds prostate cancer. The combination pill adds back small amounts of estradiol and progestin to prevent hot flashes and preserve bone mineral density.
Baird analyst Brian Skorney wrote last month that Myovant’s better bone-density profile — a loss of 0.78% compared to AbbVie’s about 3% — plus its once-daily oral regimen could give it an edge.
No hay comentarios:
Publicar un comentario